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Allergic contact dermatitis (ACD) is one of the most
common skin diseases, consisting of sensitization and
elicitation phases. With the advancement of technol-
ogy and the discovery of new types of immune cells,
our knowledge of the immunological mechanisms of
contact hypersensitivity (CHS) as a murine model of
ACD has expanded significantly in the past decade.
For example, by introducing regulatory T cells, CD4þ
T-helper 17 cells, and Langerin-positive dermal den-
dritic cells, the initiation and termination mechanism
of CHS has been revealed. In addition, the role of
mast cells in CHS, long a matter of debate, has
become apparent by developing conditional mast
cell–deficient mice. Moreover, the role of the innate
immunity system, such as that of Toll-like receptor
signaling, has made a breakthrough in this field. In
this review, we will integrate the recent advancement
of immunological mechanisms of both the sensitiza-
tion and elicitation phases of CHS into the classic
view, and we will discuss updated mechanisms on its
development and future directions.
Journal of Investigative Dermatology (2013) 133, 303–315; doi:10.1038/
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INTRODUCTION
Allergic contact dermatitis (ACD) is one of the most common
skin diseases, affecting 15–20% of the general population
worldwide (Peiser et al., 2012). It is classified as a delayed-
type hypersensitivity response, and murine contact hypersen-
sitivity (CHS) is one of the most frequently used animal models
of ACD. During the last decade, new subsets of immune cells,
such as regulatory T cells (Tregs) and CD4þ T-helper 17
(Th17) cells, have been identified in both mice and humans,
and the important roles of those cell subsets in ACD have been
implicated from studies on CHS. In addition, the discovery of
Langerin-positive dermal dendritic cells (DCs) questioned the
relevance of epidermal Langerhans cells (LCs) as key antigen-
presenting cells in cutaneous immune responses, although the
existence of DCs in humans has not been revealed yet. As a
result, some key dogmas on the development of ACD have
been changing drastically. In this review, we summarize the
recent reports of CHS, integrate recent advances into the
classic view of CHS, and discuss the updated mechanisms of
CHS development.
SECTION 1: EVENTS IN SENSITIZATION PHASE
Haptens, skin barrier function, and keratinocytes
Most of the chemicals that induce CHS are small compounds
called haptens, which typically have a molecular
mass of o500. Haptens require chemical interactions
with proteins to elicit adaptive immune responses (Lepoitte-
vin and Karlberg, 1994; Lepoittevin, 2006). Upon hapten
application, keratinocytes are activated and produce various
chemical mediators, such as tumor necrosis factor a,
IL-1b, and prostaglandin E2, which promote the migration
and maturation of skin DCs (Cumberbatch and Kimber, 1995;
Cumberbatch et al., 1997; Kabashima et al., 2003).
The skin’s barrier function prevents the entry of allergens
into the body. The first line of defense is formed by the
stratum corneum, the uppermost layer of the epidermis. In the
stratum corneum, filaggrin (FLG), a late epidermal differ-
entiation protein, has a pivotal role in barrier function. It has
been reported that loss of function variant of FLG leads to
impaired skin barrier function and is a strong predisposing
factor for atopic dermatitis (Palmer et al., 2006). FLG
mutations may also increase susceptibility to haptens,
because mutations within the FLG gene were reported to
represent a predisposition to contact allergy in both mice
(Moniaga et al., 2010) and humans (Novak et al., 2008; de
Jongh et al., 2008). On the other hand, other reports failed to
find a clear association between contact allergy risk and FLG
mutations (Lerbaek et al., 2007; Schnuch et al., 2010);
therefore, further studies are needed to confirm the associa-
tion between FLG mutation and contact dermatitis.
Tight junctions act as a second barrier to block antigen
penetration into the skin. These junctions are composed of
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several proteins, such as claudins and occludins, in the
stratum granulosum. Protein antigens are blocked from
penetrating the body by this barrier. It has recently been
reported that activated LCs can elongate their dendrites
above this barrier to take up protein antigens (Kubo et al.,
2009) and that LC deficiency leads to reduced clinical
symptoms and antigen-specific IgE production in an ovalbu-
min-induced AD model (Nakajima et al., 2012), suggesting
the important role of LCs in mediating sensitization with
protein antigens. However, because haptens are composed of
molecules that are small enough to penetrate the dermis
across the tight junction, all cutaneous DC subsets may
encounter haptens.
Roles of cutaneous DC subsets in sensitization
Until recently, LCs have been considered to be central cells
for antigen presentation in the sensitization phase of CHS
because (1) they have potent antigen-presenting ability
in vitro, (2) they exist abundantly in the epidermis, and (3)
their artificial removal by drugs, such as gliotoxin application
to the skin, results in impaired CHS response (McMinn et al.,
1990). However, novel depletion systems of LCs (Langerin-
diphtheria toxin receptor knock-in mice) have revealed that
Langerinþ dermal DCs (dDCs), but not LCs, may have a
crucial role in sensitization (Kissenpfennig et al., 2005;
Bursch et al., 2007; Wang et al., 2008). We and others have,
however, recently reported that these two populations work
in a compensatory manner to initiate sensitization (Honda
et al., 2010a; Noordegraaf et al., 2010). Consistently, Batf3-
deficient mice that lack Langerinþ dDCs exhibited a normal
CHS phenotype (Edelson et al., 2010), suggesting the
compensation of its function by other DCs.
It has also been reported that LCs have a regulatory role,
rather than a stimulatory role, during sensitization in CHS.
Research on another LC depletion system that uses the human
Langerin promoter combined with diphtheria toxin A (the
active subunit of diphtheria toxin (Kaplan et al., 2005))
revealed that congenitally LC-depleted mice exhibited an
exacerbated CHS response, suggesting that LCs may have a
suppressive function in CHS by producing IL-10 (Igyarto
et al., 2009).
Thus, although the function of LCs in sensitization remains
controversial, Langerinþ dDCs probably exert stimulatory
effects during sensitization. The function of Langerin dDCs
in sensitization has not yet been investigated intensively;
however, Langerin dDCs also appear to have stimulatory
functions in sensitization, because ablation of both LCs and
Langerinþ dDCs before sensitization impairs CHS response
but is unable to abrogate it completely (Bursch et al., 2007;
Wang et al., 2008; Honda et al., 2010a).
As antigen presentation is required for both the sensitiza-
tion phase and the elicitation phase of CHS, it is important to
assess the relevance of DC subtypes in both phases
separately. We previously demonstrated that the depletion
of skin DCs in hapten-sensitized mice enhanced the effector
phase of CHS (Grabbe et al., 1995). This suggests the
existence of some DC subsets that have a regulatory function
in the elicitation phase.
In certain situations, it has been reported that LCs and
Langerinþ dDCs have completely distinct roles. For example,
in a gene-gun immunization model, LCs mediated the
production of Th2-type Ig, IgG1, whereas Langerinþ dDCs
mediated Th1-type Ig, IgG2a (Nagao et al., 2009). In a
cutaneous candida infection model, LCs induced Th17 cells,
whereas Langerinþ dDCs promoted Th1 cells (Igyarto et al.,
2011). In addition, LCs induced Tregs in UV- or skin
graft–induced immunosuppression (Yoshiki et al., 2009,
2010; Schwarz et al., 2010). Thus, LCs may have both
positive and negative immunological functions in a context-
dependent manner.
Innate immune activation
As mentioned earlier, full activation of DCs is essential for the
establishment of sensitization with haptens. However, the
molecular mechanisms that explain how haptens activate
DCs remain unknown. Martin et al. have intensively
investigated the involvement of the innate immunity system
in hapten-induced DC activation, and they have reviewed
this aspect comprehensively (Martin et al., 2011).
Innate immunity is activated through pattern recognition
receptors, such as membrane-associated Toll-like receptors
(TLRs) and cytosolic nucleotide-binding oligomerization
domain (NOD)-like receptors (NLRs). DCs are activated
through the cooperation of these two pathways (Martin et al.,
2011). Among TLRs, TLR2 and TLR4 have a critical role in
DC maturation in CHS induced with trinitrochlorobenzene
(TNCB), oxazolone (Ox), and FITC (Martin et al., 2008). The
endogenous ligands for these receptors might be generated by
hapten-induced degradation of extracellular matrix via
reactive oxygen species from DCs (Bruchhausen et al.,
2003; Matsue et al., 2003; Mehrotra et al., 2005), because
haptens can induce the production of reactive oxygen species
in DCs in vitro (Soltes et al., 2006; Stern et al., 2007; Naik
and Dixit, 2011). For example, biglycan, a derivative from
extracellular matrix, is a possible candidate for the endogen-
ous TLR2/4 ligand and an activator of NACHT, LRR, and
pyrin (NALP) 3 inflammasome of NLRP3 (Schaefer et al.,
2005; Babelova et al., 2009). Hyaluronic acid is also
degraded by reactive oxygen species, and blocking of the
hyaluronic acid degradation significantly reduced sensitiza-
tion for CHS, suggesting the degraded hyaluronic acid as
another endogenous activator of TLR2/4 signaling in CHS
(Martin et al., 2008).
Nickel (Ni2þ ) is one of the most frequent causes of
contact dermatitis in humans, although it rarely occurs in
mice. Earlier studies have reported that coadministration of
adjuvant, such as complete Freund’s adjuvant or lipopoly-
saccharide, efficiently induced Ni2þ allergy in mice,
suggesting the important role of TLR4 signaling in efficient
sensitization with Ni2þ . Very recently, Schmidt et al.
(2010) reported that Ni2þ directly activates human TLR4
but not mouse TLR4 and that the transgenic expression of
human TLR4 in TLR4-deficient mice resulted in efficient
sensitization and elicitation to Ni2þ . These reports indicate
the crucial roles of TLR4 in Ni2þ allergy in both mice and
humans.
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Haptens also activate keratinocytes in an NLR-dependent
manner. Among the NLR family, NLRP3 controls the
production of proinflammatory cytokines through activation
of caspase-1. Without NLRP3 or its adaptor protein ASC
(Sutterwala et al., 2006; Watanabe et al., 2007a, 2008), the
production of IL-1b and IL-18 from keratinocytes was
inhibited, which resulted in impaired DC migration and T-
cell priming and led to impaired CHS (Antonopoulos et al.,
2001; Nakae et al., 2003; Antonopoulos et al., 2008).
The adenosine triphosphate (ATP) and purinergic receptor
P2X7-dependent pathways have been reported as being
crucial for NLRP3 inflammasome activation by contact
allergens. ATP is the main energy carrier within cells.
Stressed, damaged, or dying cells release ATP into the
extracellular space, which interacts with purinergic receptors
on different immune and structural cells. Triggering of P2X7,
a kind of ligand-gated ion channel (Surprenant and North,
2009), by ATP induces the activation of the NLRP3
inflammasome through Kþ efflux from the cell (Martinon
et al., 2009). Loss of ATP-P2X7 signaling results in the failure
of NLRP3 activation, which leads to impaired sensitization
capacity of DCs and absence of CHS in P2X7-deficient mice
(Weber et al., 2010). Indeed, contact allergens, such as TNCB
and Ox, induce the release of ATP from skin cells in vivo
(Martin et al., 2011). In addition to NLRP3, NLRP12 regulates
sensitization in CHS. NLRP12 is expressed on DCs and
neutrophils, and a lack of NLRP12 resulted in the impaired
migration of skin DCs to draining lymph nodes (dLNs) and
neutrophil infiltration into the skin, leading to severely
impaired CHS (Arthur et al., 2010).
Together, these hapten-induced irritant effects through
innate immune systems are essential for the activation of
cutaneous antigen-presenting cells (Figure 1) and thereby
determine the allergenic potential of a hapten during the
sensitization phase. During the elicitation phase of CHS, they
induce the activation of skin endothelial cells and thereby
initiate the inflammatory response via antigen nonspecific
mechanisms.
Activation of mast cells
The role of mast cells in CHS has been controversial. In some
studies, mast cell–deficient mice exhibited reduced inflam-
mation in TNCB-induced CHS (Askenase et al., 1983;
Biedermann et al., 2000). Other studies reported undimin-
ished CHS induced with TNCB or DNFB (Galli and Hammel,
1984; Mekori and Galli, 1985). Furthermore, a recent
publication reported that mast cells have regulatory roles
through the production of IL-10, as mast cell–deficient mice
exhibited enhanced urushiol and DNFB-induced CHS
(Grimbaldeston et al., 2007). In these studies, however, mice
carrying mutations in the stem cell factor or its receptor c-Kit
were used as mast cell–deficient mice (C57BL/6-KitWsh/Wsh
or WBB6F1-Kitw/wv). Although these mice lack mast cells,
they also have various other immunological alterations,
making it difficult to form a conclusion regarding the role
of mast cells in CHS.
Recently, a novel mast cell ablation system was established
by two independent groups (Dudeck et al., 2011; Otsuka
et al., 2011). In these mice, mast cells can be conditionally
depleted through the administration of diphtheria toxin. Both
groups reported that mice depleted of mast cells exhibited
reduced CHS induced with FITC or Ox (Dudeck et al., 2011)
and also with DNFB or Ox (Otsuka et al., 2011). In addition,
mast cell–specific deletion of IL-10 did not result in
exacerbated CHS. Without mast cells, skin DC migration/
maturation and T-cell priming in the sensitization phase were
Hapten
ROS
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Ni2+
hTLR4
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Figure 1. Activation of the innate immune system by contact allergens (haptens, Ni2þ ). Dendritic cells (DCs) are activated by haptens directly or indirectly
through degraded hyaluronic acid (HA)-TLR2/4 signaling, which induces pro-IL-1b and pro-IL-18 transcription. Adenosine triphosphate (ATP)-P2X7 signaling
activates NLRP3, which results in caspase-1 activation and the production of the biologically active form of IL-1b and IL-18. These cytokines induce DC maturation
and migration toward draining lymph nodes; and they contribute to the sensitization process. IL-1b and IL-18 from neighboring cells such as keratinocytes (KCs)
are also important in this process. ASC, apoptosis-associated speck-like protein containing a caspase recruitment domain; ROS, reactive oxygen species.
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impaired. Mast cells stimulated DCs via ICAM-1 or lympho-
cyte function–associated antigen 1 interaction and by
membrane-bound tumor necrosis factor a on mast cells.
Interestingly, activated DCs in turn increased Ca2þ influx in
mast cells, suggesting that mast cells and DCs interact to
activate each other. In the elicitation phase, mast cell
deficiency resulted in an impaired CHS response, probably
as a result of reduced vascular permeability caused by a loss
of histamine release from mast cells (Dudeck et al., 2011).
To date, it remains unknown why there is such a
discrepancy between the reports using stem cell factor or c-
Kit–deficient models and those using conditional mast cell
ablation models. One of the differences between these two
models is the existence of melanocytes and hematopoietic
stem cells. Recently, melanocytes were shown to express
TLRs to modulate immune responses and to produce IL-1a
and IL-1b (Swope et al., 1994; Yu et al., 2009). In addition,
because of the congenital absence of mast cells in KitW/Wv
and KitWsh/Wsh mice, a compensatory mechanism may
exist, such as the repopulation of the skin with basophils
(Piliponsky et al., 2010). Therefore, KitW/Wv and KitWsh/Wsh
mice may not necessarily be appropriate to evaluate the
exclusive roles of mast cells.
SECTION 2: EVENTS IN ELICITATION PHASE
Antigen-nonspecific inflammation: keratinocytes, mast cells,
and neutrophil activation
The mechanism of inflammatory cell infiltration in the
elicitation phase has been explained using both antigen-
nonspecific and -specific inflammatory signals (Grabbe
et al., 1996; Grabbe and Schwarz, 1998). Following
antigen-nonspecific inflammation, antigen-specific T cells
are recruited to the inflammatory sites and are activated by
the antigen, which causes antigen-specific inflammation.
Keratinocytes, neutrophils, and mast cells are the main
factors to create the antigen-nonspecific inflammation at
elicitation. First, haptens stimulate keratinocytes to produce
proinflammatory cytokines such as IL-1b and tumor necrosis
factor a in an NLR-dependent manner (Sutterwala et al.,
2006; Watanabe et al., 2007a). Those cytokines then activate
vascular endothelial cells to express adhesion molecules,
such as ICAM-1 and P/E-selectins, which guide T cells in the
blood to transmigrate to tissues. Haptens also increase
vascular permeability through mast cell–derived histamine
(Dudeck et al., 2011), which helps neutrophils to infiltrate
the skin. In addition, haptens activate mast cells and
keratinocytes to produce neutrophil-recruiting chemokines,
such as CXCL1 and CXCL2, which further contribute to
neutrophil recruitment (Biedermann et al., 2000; Honda
et al., 2009). The initial neutrophil recruitment is proposed to
be essential for subsequent T-cell infiltration, because the
depletion of neutrophils reduces CD8þ T-cell infiltration
and leads to impaired CHS (Dilulio et al., 1999; Engeman
et al., 2004). Indeed, one of the immunosuppressive
mechanisms of the action of topical steroids in CHS may
be mediated through its inhibition of neutrophil and
macrophage functions, not by T-cell or keratinocyte func-
tions (Tuckermann et al., 2007).
Overall, the aforementioned mechanism creates the first
round of antigen-nonspecific inflammation, which is an
important step for subsequent antigen-specific inflammation.
Indeed, when the concentration of haptens is not high enough
to provoke this antigen-nonspecific inflammation, no CHS
reaction occurs (Grabbe et al., 1996) (see Figures 1 and 2).
Antigen-specific inflammation: T-cell activation
Following the antigen-nonspecific inflammation, T cell–
mediated antigen-specific inflammation is initiated. When T
cells infiltrate into the skin, they are activated by cutaneous
antigen-presenting cells, and they produce cytokines, such as
IFN-g and IL-17. In fact, stable interaction between skin DCs
and T cells was observed in live imaging analysis (Egawa et al.,
2011), and inhibition of CD86 expression by siRNA resulted
in reduced inflammation (Ritprajak et al., 2008), suggesting
that effector T cells are activated locally by hapten-carrying
antigen-presenting cells.
Cytokines produced by activated T cells then stimulate
skin-resident cells, which leads to further recruitment of T
cells, amplifying the inflammation. Each T-cell subset (i.e.,
Th1/T-cytotoxic (Tc) 1, Th2, and Th17/Tc17) activates the
skin-resident cells differently and forms their specific type of
inflammation. For example, the expression level of CXCL9 in
wild-type mice and IL-17 receptor–deficient mice in DNFB-
induced CHS skin lesions was comparable, whereas the
expression level in IFN-g receptor–deficient mice was
marginal, indicating the importance of IFN-g signaling for
CXCL9 induction. In contrast, CXCL1 was strongly expressed
in IFN-g receptor–deficient mice, whereas its expression was
significantly reduced in IL-17 receptor–deficient mice (He
et al., 2009). The importance of each cytokine in the
development of CHS will be discussed again in the latter
part of this section.
Kinetics of histological change and chemokine expression
In TNCB-induced CHS, capillary vasodilation occurs within 3
hours after the challenge, and neutrophils accumulate in the
skin around 6 hours later. Lymphocytes then start to infiltrate
into the skin within 12 hours after the challenge, and massive
infiltration of lymphocytes and to a lesser extent of
neutrophils constitutes the inflammatory cells 24 hours after
the challenge (Mitsui et al., 2003, 2004). Differential and
sequential expressions of multiple chemoattractant factors,
mainly chemokines, regulate such sequential cell infiltration
patterns. Mitsui et al. (2003) have analyzed the kinetic
profiles of chemokine mRNA expression using microarray
analysis, and they classified the chemokines into four groups
based on their kinetic pattern. At the early time point (3 hours
post challenge), the expression level of neutrophil-recruiting
chemokines, such as CXCL1, is increased, and that of
lymphocyte-recruiting chemokines, such as CXCL9 and
CXCL10, is increased around 6–9 hours post challenge and
sustained until at least 24 hours post challenge, which
corresponds well with the time course of the histological
findings (Mitsui et al., 2003).
In human ACD, on the other hand, the cell infiltration and
chemokine expression patterns are slightly different from
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those in CHS. Goebeler et al. (2001) analyzed the kinetics of
cell infiltration and chemokine mRNA expression in patients
after a patch test. CCL2 was detected 6 hours after the
challenge, followed by CCL5 and CCL22 expressions within
12 hours. Thereafter, expression of CXCL9, CXCL10, CCL17,
and CCL18 reached maximum levels at 72 hours (Goebeler
et al., 2001). The expression levels of neutrophil-attracting
chemokines, such as CXCL1 and CXCL2, were weak.
Although the histology did not exhibit significant changes 6
hours after the antigen challenge, inflammatory cells began to
appear 12 hours after the challenge and remained for at
least 96 hours. CD3þ cells were the most dominant type of
cells at all time points. The second most dominant cells were
CD68þ macrophages, and neutrophils were relatively fewer
than other cell types. It remains to be elucidated whether
neutrophils are prerequisites for subsequent cell infiltration
in ACD. In addition, the role of macrophages at the elicitation
phase remains unclear and should be pursued in future
studies.
Keratinocytes are the most important source of chemokine
production. The activated keratinocytes produce multiple
chemokines, such as CXCL1, CXCL2, CXCL9, CXCL10,
CCL8, CCL17, and CCL27 (Flier et al., 2001; Karsak et al.,
2007; Mori et al., 2008; Honda et al., 2009). CXCL10 is a
ligand for CXCR3, which is strongly expressed on Th1 cells.
Blockade of CXCL10 and CXCL10-deficient mice exhibited
reduced TNCB-induced CHS in C57BL/6 mice (Nakae et al.,
2003) or DNFB-induced CHS in 129Sv/C57BL/6 F1 mice,
indicating the important role of CXCL10-CXCR3 signaling for
T-cell infiltration. The CCL27-CCR10 and CCL17/22-CCR4
axes constitute another important mechanism for T-cell
recruitment to skin (Reiss et al., 2001; Homey et al., 2002;
Wang et al., 2010). Although the blocking effect of these
chemokines was reported differently depending on the model
used, as shown in Table 1, this is likely related to the
dominant T-cell subsets induced under each experimental
condition. Neutrophil-recruiting chemokines also have im-
portant roles, because a blockade of CXCL1 or a deficiency of
its receptor (CXCR2) leads to reduced CHS (Dilulio et al.,
1999; Cattani et al., 2006) induced by TNCB and/or DNFB.
Infiltrated T cells then stimulate the neighboring cells to
produce cytokines and chemokines, which create a positive
feedback loop of T-cell infiltration and local chemokine
production. The activated T cells, as well as other inflam-
matory cells, contribute to dermal edema and epidermal
spongiosis, which peaks 24–48 hours after hapten challenge.
It has been proposed that IFN-g-producing T cells trigger Fas-
induced apoptosis of keratinocytes (Trautmann et al., 2000)
and that cytokine-activated keratinocytes produce hyaluro-
nan and decrease E-cadherin expression, which leads to
spongiosis (Ohtani et al., 2009).
Effector cells: CD4þ and CD8þ T cells
CHS was first considered to be a CD4þ T cell–mediated
response as a representative of delayed-type hypersensitivity,
but it is now recognized that both CD4þ and CD8þ T cells
Sensitization phase
Hapten
Epidermis
Dermis
Step 1
LCs
Cytokine, chemokine, lipid mediator
Mast cell
TLR2/4
Innate immune
stimulation
Afferent lymphatics
LNs
Treg
Naive T cells
Ag presentation
Memory T cell differentiation and proliferation
Step 3 Memory T cells
Efferent lymphatics
Step 2 DC migration and maturation
dDCs: Langerin+ or–
KCs
Activation of innate immune system (KCs, DCs, and mast cells)
Figure 2. A schematic view of the sensitization phase. Step 1: Haptens activate keratinocytes (KCs) and mast cells directly or indirectly through innate immune
systems. The activated KCs and mast cells produce various chemical mediators, which activate cutaneous dendritic cells (DCs). Step 2: The activated DCs
capture antigens, start maturation, and migrate to the dLNs via afferent lymphatics. Step 3: Migrated DCs present antigen to naive T cells in dLNs. Antigen-
specific clones differentiate and proliferate into effector T cells. Tregs affect DC function and have a suppressive role in effector T-cell generation. dDC, dermal
DC; dLNs, draining lymph nodes; LC, Langerhans cell; LN, lymph node; Tc, T cytotoxic; Th, T helper; Treg, regulatory T cell.
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are important in the elicitation of CHS. Gocinski and Tigelaar
(1990) first revealed the distinct function of T-cell subsets by
performing antibody depletion experiments. Through deple-
tion of CD8þ T cells in the elicitation phase, the CHS
response was reduced, whereas depletion of CD4þ T cells in
either the sensitization phase or the elicitation phase resulted
in an enhanced and prolonged response, suggesting that
CD8þ T cells have effector functions, whereas CD4þ T cells
have regulatory roles (Gocinski and Tigelaar, 1990; Bour
et al., 1995; Xu et al., 1996; He et al., 2009). However, the
simultaneous depletion of both CD8þ and CD4þ T cells at
the elicitation phase further reduced the CHS response,
suggesting that CD4þ T cells contain both effector and
regulatory populations (Gocinski and Tigelaar, 1990; Waka-
bayashi et al., 2005).
The establishment of gene-targeting mice that lack CD4þ
(major histocompatibility complex (MHC) class II–deficient
mice) and CD8þ (MHC class I–deficient mice) T cells is
another approach for investigating the role of T-cell subsets in
CHS. In MHC class I–deficient mice, the CHS response was
completely absent, whereas MHC class II–deficient mice
developed enhanced reactions (Bour et al., 1995). In another
report, however, MHC class II–deficient mice exhibited
reduced CHS (Takeshita et al., 2004a). CD4-deficient mice,
which have no CD4þ T cells (Tyznik et al., 2004; Saint-
Mezard et al., 2005), exhibited an impaired CHS response
(Kondo et al., 1996; Wang et al., 2000). In adoptive transfer
experiments, the transfer of either CD8þ or CD4þ T cells
induced CHS (Gautam et al., 1991; Vocanson et al., 2006;
He et al., 2009). Taken together, these studies indicate that
CD8þ T cells mainly have proinflammatory effector func-
tions, whereas CD4þ T cells have both proinflammatory and
anti-inflammatory functions that are dependent on their
cytokine production pattern or subset, as we discuss in the
next section.
Effector cytokines in the elicitation phase: the role
of Th1/Tc1, Th2/Tc2, and Th17/Tc17
CD4þ Th cells and CD8þ Tc cells can be subdivided into at
least three subsets that are relevant for cutaneous immune
responses: Th1/Tc1, Th2/Tc2, and Th17/Tc17 cells. Th1/Tc1
cells are characterized by the secretion of IFN-g; Th2/Tc2
cells by IL-4, IL-5, and IL-13; and Th17/Tc17 cells by IL-17A
and IL-22 production (Weaver et al., 2007). As high levels of
IFN-g and an accumulation of Th1/Tc1 cells were observed at
the elicitation sites, it was previously believed that CHS was
mainly mediated by Th1/Tc1 and regulated by Th2 cells
(Grabbe and Schwarz, 1998). However, as each hapten may
have its own properties to induce a dominant type of Th/Tc
subset, and the type of mouse strain used can also influence
the results, we have to consider these factors when
interpreting the role of each T-cell subset in CHS. Table 2
shows a summary of previous reports discussing the role of
IFN-g, IL-4, and IL-17 in CHS. Typical haptens used in CHS
include TNCB, DNFB, Ox, and FITC. Among them, TNCB,
DNFB, and Ox have generally been regarded as Th1 IFN-g-
Table 1. Summary of the roles of chemokines and chemokine receptors in CHS
Hapten
Chemokine/chemokine
receptor Mouse strain CHS response Reference
Proposed phase of
involvement/note
TNCB Anti-CXCL10 antibody C57BL/6 Impaired Nakae et al. (2003) Elicitation phase
Ox Anti-CXCL1 antibody BALB/c Impaired Dilulio et al. (1999) Elicitation phase
CXCR2 KO BALB/c Impaired Cattani et al. (2006)
Anti-CCL27 antibody BALB/c Impaired Wang et al. (2010) Elicitation phase
CCL27 Tg C57BL/6 Normal Kagami et al. (2008)
Anti-CCL17 antibody BALB/c Normal Wang et al. (2010) Elicitation phase
Anti-CCL22 antibody BALB/c Normal Wang et al. (2010) Elicitation phase
Anti-CCL17/22 antibody BALB/c Impaired Wang et al. (2010) Elicitation phase
DNFB Anti-CXCL1 antibody BALB/c Impaired Dilulio et al. (1999) Elicitation phase
CXCR2 KO BALB/c Impaired Cattani et al. (2006)
CXCL10 KO 129sv/C57BL/6 F1 Impaired Dufour et al. (2002)
Anti-CCL27 antibody BALB/c Impaired Homey et al. (2002) Elicitation phase
Anti-CCL27 antibody C57BL/6 Normal Reiss et al. (2001) Elicitation phase
CCR4 KO C57BL/6 Normal Reiss et al. (2001) Elicitation phase
CCR4 KO plus anti-CCL27 antibody C57BL/6 Impaired Reiss et al. (2001) Elicitation phase
FITC CCL27 Tg C57BL/6 Normal Kagami et al. (2008)
Anti-CXCL1 antibody BALB/c Impaired Takeshita et al. (2004b) Elicitation phase
Anti-CXCL2 antibody BALB/c Impaired Takeshita et al. (2004b) Elicitation phase
Abbreviations: CHS, contact hypersensitivity; Ox, oxazolone; TNCB, trinitrochlorobenzene.
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Table 2. Summary of the roles of cytokines in CHS
Hapten Cytokine Mouse strain CHS response Reference
Proposed phase of
involvement/note
TNCB IFN-g KO C57BL/6 Impaired Mori et al. (2008) Elicitation phase
IFN-g KO C57BL/6 Normal Nakae et al. (2003)
IFN-g KO BALB/c Normal Nakae et al. (2003)
IFN-g receptor KO 129sv Normal Saulnier et al. (1995) Reduced inflammatory cell infiltration
r-IL-4 BALB/c Impaired Biedermann et al. (2001) Elicitation phase
Transfer of Th2 cells BALB/c Impaired Biedermann et al. (2001) Elicitation phase
r-IL-4 C3H/HeN Normal Gautam et al. (1992) Sensitization phase
r-IL-4 CeH/HeN Impaired Gautam et al. (1992) Elicitation phase
Anti–IL-4 antibody C3H/HeN Normal Gautam et al. (1992) Sensitization phase
Anti–IL-4 antibody C3H/HeN Increased Gautam et al. (1992) Elicitation phase
Anti–IL-4 antibody CBA/J Normal Salerno et al. (1995) Sensitization phase
Anti–IL-4 antibody CBA/J Impaired Salerno et al. (1995) Elicitation phase
IL-4 KO C57BL/6 Impaired Dieli et al. (1999)
r-IL-4 C57BL/6 Increased Dieli et al. (1999) Elicitation phase
STAT6 KO C57BL/6 Impaired Yokozeki et al. (2000) Sensitization
Anti–IL-4 antibody BALB/c Increased Asada et al. (1997)
IL-17AKO 129/C57BL/6 F1 Impaired Nakae et al. (2002) Sensitization
Ox IFN-g receptor KO 129Sv Normal Saulnier et al. (1995) Reduced inflammatory cell infiltration
IL-4 KO BALB/c Normal Traidl et al. (1999)
IL-4 KO 129J Normal Berg et al. (1995)
IL-4 KO C57BL/6 Normal Berg et al. (1995)
IL-4 KO C57BL/6 Normal Dieli et al. (1999)
STAT6 KO C57BL/6 Impaired Yokozeki et al. (2000)
DNFB IFN-g receptor KO C57BL/6 Normal Reeve et al. (1999)
IFN-g receptor KO C57BL/6 Impaired He et al. (2009) Elicitation phase
Anti–IFN-g antibody C57BL/6 Normal He et al. (2006) Elicitation phase
IFN-g KO C57BL/6 Impaired Mori et al. (2008) Elicitation phase
STAT6 KO C57BL/6 Impaired Yokozeki et al. (2000)
STAT6 KO C57BL/6 Increased Takeshita et al. (2004a)
IL-4 KO C57BL/6 Impaired Weigmann et al. (1997) Late phase reaction
IL-4 KO BALB/c Impaired Traidl et al. (1999)
IL-13 KO C57BL/6 Increased Herrick et al. (2003)
IL-17A KO 129/C57BL/6 F1 Impaired Nakae et al. (2002)
IL-17R KO C57BL/6 Impaired He et al. (2009) Elicitation phase
Anti–IL-17 antibody C57BL/6 Increased He et al. (2009) Elicitation phase
FITC IFN-gR2 KO C57BL/6/129sv Impaired Lu et al. (1998)
r-IFN-g BALB/c Impaired Takeshita et al. (2004a) Sensitization phase
Anti–IL-4 antibody BALB/c Impaired Takeshita et al. (2004a) Sensitization phase
IFN-g KO C57BL/6 Impaired Mori et al. (2008) Elicitation phase
STAT6 KO C57BL/6 Impaired Takeshita et al. (2004a)
Abbreviations: CHS, contact hypersensitivity; Ox, oxazolone; Th, T helper; TNCB, trinitrochlorobenzene.
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inducing haptens, whereas FITC is regarded as inducing Th2
IL-4, possibly owing to the adjuvant effects by dibutyl
phthalate, which is used as a standard solvent for FITC
(Larson et al., 2010).
However, as shown in Table 2, several conflicting results
have been reported even among the same hapten-mouse
strain combination, especially with regard to the role of IFN-g
and IL-4. For example, a normal ear-swelling response was
demonstrated in IFN-g–deficient mice in both a C57BL/6 and
a BALB/c background in TNCB-induced CHS (Nakae et al.,
2003). However, another group reported that IFN-g–deficient
mice in a C57BL/6 background exhibited reduced ear
swelling in CHS induced by three different haptens (TNCB,
DNFB, and FITC) (Mori et al., 2008). They concluded that
IFN-g acted on keratinocytes to produce Th1 chemokines,
which lead inflammatory cell infiltration into the skin during
the elicitation phase of CHS (Mori et al., 2008). As for IL-4,
administration of an IL-4-blocking antibody exacerbated
(C3H/HeN) (Gautam et al., 1992) or decreased (CBA/J)
(Salerno et al., 1995) in TNCB-induced CHS. Deficiency of
the STAT6 that transmits IL-4/13 signaling resulted in reduced
(Yokozeki et al., 2000) or increased (Takeshita et al., 2004a)
ear swelling in DNFB-induced CHS in a C57BL/6 back-
ground. It has been reported that IL-17 has a stimulatory role
in both the sensitization phase (Nakae et al., 2002) and the
effector phase (He et al., 2009), and no contradictory results
have been reported so far. As IL-17 is produced by many
other cells, such as gd T cells and neutrophils, it would be
interesting to investigate the contribution of IL-17 produced
by each cell population in the development of CHS.
Although there is no clear explanation of why such a
discrepancy exists, experimental data on the relative im-
portance of T-cell subsets for the elicitation of CHS appear to
depend on the experimental model used. Indeed, the relevant
factors that determine the polarization of the emerging
antigen-specific T cells during the priming/sensitization phase
of CHS may be the microenvironment in which the antigen is
first presented (skin vs. other body sites; normal vs. inflamed
skin) and the type of antigens and the genetic background of
the individual. Moreover, ongoing immune responses against
microbiota in the animal housing facility may also affect the
type of T-cell responses generated in this context. Similarly,
the skin microenvironment may also regulate which T-cell
subsets are activated during the effector phase of CHS.
Other mechanisms in antigen-specific inflammation:
involvement of B cells and natural killer T cells
B cells and natural killer T cells may also contribute to the
development of CHS, although their relative importance to
this type of immune response remains unclear. It has been
demonstrated that IL-4-producing invariant natural killer T
cells in the liver were activated by hapten application
(Campos et al., 2006a, 2006b) and promoted the migration
of peritoneal B1-like B cells to lymphoid organs and their
production of hapten-specific IgM. In the elicitation phase,
hapten-specific IgM can bind to the haptens and activate a
complement to generate C5a (Tsuji et al., 2002). C5a then
stimulates mast cells and platelets, which release serotonin
and tumor necrosis factor a, leading to local endothelial
activation and subsequent inflammation (Tsuji et al., 2000;
Tamagawa-Mineoka et al., 2007).
Regulation of inflammation: Regulatory T cells and B cells
Evidence has accumulated regarding the regulatory mechan-
isms of Tregs in CHS (Honda et al., 2011). Transfer of Tregs
before elicitation suppresses the ear-swelling response, for
which several different suppression mechanisms have been
proposed. The first is that IL-10 from Tregs inhibits leukocyte
influx into the skin by downregulating E/P-selectin expression
in blood endothelial cells (Ring et al., 2006). The second is
through an adenosine-mediated mechanism. Tregs generate
adenosine by the degradation of ATP through CD39/73,
which is strongly expressed on Tregs. Adenosine can act as a
suppressor of leukocyte activation and can also block
leukocyte influx into the skin by downregulating E/P-selectin
expression in blood endothelial cells (Ring et al., 2009).
However, ATP is not just a substrate for the generation of
adenosine, it also activates the immunosuppressive function
of Tregs through its receptor P2X7 (Ring et al., 2010a). Tregs
from IL-10–deficient mice had poor ability to produce
adenosine and were not activated by ATP, despite the
equivalent expression of CD39/73 and P2X7 (Ring et al.,
2011); this suggests that the impaired suppression ability of
IL-10–deficient Tregs is not solely attributable to the loss of
IL-10 production. Transfer of Tregs during the sensitization
phase also suppresses CHS. Tregs in lymph nodes acquire an
activated phenotype through ATP, and the activated Tregs
establish gap junctions with DCs in lymph nodes, which
causes a reduction in the capacity of DCs to stimulate CD8þ
T cells (Ring et al., 2010b).
Although the exogenous transfer of Tregs can suppress
inflammation, the extent to which the endogenous Tregs
contribute to the suppression of CHS was unknown. To
address this issue, Treg-specific depletion in vivo is required.
As Foxp3 is a transcriptional factor for Tregs and exists
intracellularly, depletion of Tregs by a neutralizing antibody
was technically difficult. To solve this problem, Foxp3 reporter
mice expressing human CD2 and CD52 chimeric protein have
been generated and designated as Foxp3hCD2/hCD52 mice
(Tomura et al., 2010). In the mice, because Foxp3þ cells
coexpress hCD2/hCD52 on the cellular surface, Foxp3þ Tregs
are depleted with neutralizing anti-hCD52 antibody. When
Tregs were depleted during the sensitization phase, it caused
higher effector CD4þ and CD8þ T-cell induction and led to
enhanced and prolonged ear swelling, indicating that endo-
genous Tregs contribute significantly to the control of
sensitization (Honda et al., 2010b). In addition, Vocanson
et al. (Vocanson et al., 2006) have reported that, by depleting
CD4þ T cells before sensitization, CHS developed in mice
with the weak hapten. This did not normally induce CHS in
mice, and it therefore suggests the suppressive role of
endogenous Tregs in sensitization.
When Tregs were depleted during the elicitation phase, it
also led to an enhanced and prolonged ear-swelling
response, indicating the importance of Tregs in the termina-
tion of inflammation (Tomura et al., 2010). In fact, the
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number of Tregs in skin significantly increased during the
process of skin inflammation, suggesting that Tregs have a
suppressive role at inflammatory sites. It was reported that
CCR4 is a critical receptor for Treg migration into skin under
homeostatic conditions (Dudda et al., 2008). A recent report,
however, indicates that loss of CCR4 does not necessarily
inhibit Treg migration in the elicitation site, because CCR4-
deficient mice exhibited a similar or even elevated number of
Tregs in the skin after elicitation (Lehtimaki et al., 2010). In
the context of CHS, other chemokine receptors, such as
CCR10, may compensate for the function of CCR4.
Recirculation of Tregs from skin to the dLNs
Although a number of studies have been conducted to dissect
the T cell–infiltration mechanisms to skin, it remained unclear
how and to where T cells migrate after the infiltration. Using
a new cell-labeling system with the photo-convertible protein
Kaede, we succeeded in tracking the migration of T cells after
their infiltration into the skin. When Kaede protein is
irradiated with violet light, its fluorescence turns from green
to red, which enables us to label the cells for tracking their
mobilization. Using this system, it was reported that skin-
infiltrated T cells moved from skin to dLNs in both the steady
and inflammatory conditions (Tomura et al., 2010). In
addition, Tregs migrated rather selectively in the inflamma-
tory condition (elicitation phase) than in the steady condition.
Moreover, Tregs that circulated to dLNs had a potential to
remigrate into the skin. Although the mechanism of how
Tregs migrate from skin to dLNs remains unclear, skin Tregs
may use CCR7-dependent mechanisms for their entry into
lymph vessels (Kabashima et al., unpublished observation).
Interestingly, the skin-derived Tregs exhibited an activated
phenotype with high expression of cytotoxic T-lymphocyte
antigen-4 (CTLA-4) and IL-10, and they had much more
potent suppressive activities compared with resident Tregs in
the dLNs, suggesting that skin Tregs exert their potent
suppressive activity not only in skin but also in dLNs by
circulating in the body.
Importantly, using the above cell-labeling systems, we
observed that other skin-infiltrated cells, such as non-Treg
CD4þ T cells and CD8þ T cells, migrated from the skin to
dLNs (Kabashima et al., unpublished observation). The
function analyses of those skin-derived cells, which will
further clarify the complex regulatory mechanisms of CHS,
are now ongoing.
In addition to Tregs, the involvement of regulatory B cells
(Bregs) has also been proposed as another regulatory
mechanism in CHS. Bregs are identified as a CD1bhighCD5þ
B-cell population (Bouaziz et al., 2008). They represent 1–2%
of spleen B220þ cells and produce abundant amounts of IL-
10 (Yanaba et al., 2008). CD19-deficient mice exhibited
augmented CHS responses, and the transfer of Bregs into
CD19-deficient mice normalized the extent of inflammation
in CHS (Watanabe et al., 2007b).
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Figure 3. A schematic view of the elicitation phase. Step 1: Upon reexposure to haptens, keratinocytes (KCs) and mast cells are activated and produce
various chemical mediators, which activate endothelial cells and cause inflammatory cell infiltration, including antigen-specific T cells. Step 2: Infiltrated
antigen-specific effector T cells are activated and produce proinflammatory cytokines and chemokines, which activate KCs and cause further inflammatory
cell infiltration. Step 3: In addition to effector T cells, Tregs infiltrate inflammatory sites and exert a suppressive function. Some infiltrated Tregs return to
dLNs and may contribute to the resolution of inflammation. Ag, antigen; dDC, dermal DC; dLNs, draining lymph nodes; LC, Langerhans cell; LN, lymph node;
Tc, T cytotoxic; Th, T helper; Treg, regulatory T cell.
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CONCLUSION AND DISCUSSION
Taken together, the broad view of CHS development during
the sensitization and elicitation phases is summarized in
Figures 2 and 3. By integrating the newly identified cell
subsets and by introducing innate immunity into CHS, our
understanding of the mechanisms of CHS has significantly
advanced compared with a decade ago. At the same time,
however, some key questions remain unanswered, such as
the role of LCs in the sensitization phase and the identifica-
tion of the responsible DC subsets in the elicitation phase.
These questions should be examined in future research.
The heterogeneity of the mechanism of CHS may be
another important point to be addressed. Although multiple
T-cell subsets or cytokines have been reported to be involved
in the development of CHS, their relative importance appears
to depend upon the experimental model used. This is
probably attributable to the fact that CHS is created by the
cooperation of multiple factors, such as the microenviron-
ment in which the antigen is presented, the type of antigen
itself, and the subject’s genetic background. Systemic
analysis of these factors from the viewpoints of innate
immunity may also provide important clues and enhance
our understanding (Table 3).
Therefore, the CHS model has provided us with valuable
lessons on the mechanisms of ACD as discussed above;
however, there still remains a compelling need to reveal whe-
ther such findings in CHS are relevant to human ACD. Future
studies focusing on this topic will develop novel therapeutic
approaches to control cutaneous inflammatory diseases.
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